Coronavirus: what is the science behind UK plan to delay second dose of vaccines?
Experts divided over move to broaden gap between the two jabs in order to inoculate more people
Governments and health experts worldwide are considering whether to follow the UK in inoculating as many people as possible against Covid by giving them each just one dose rather than two.
The debate has been raging since the end of December, when Boris Johnson’s government announced plans to postpone giving the second dose of both the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines by up to 12 weeks.
Denmark has now unveiled plans to delay the second dose of both the Pfizer and forthcoming Moderna jabs by up to six weeks, and Germany is considering a similar move.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
But some experts are warning that “delaying could cause further virus mutations and render the shot ineffective”, while others “question whether recipients will be left more vulnerable”, says Politico.
“The only thing that is clear is that a second vaccination is absolutely essential because it triggers the necessary immune response, like a kind of booster,” adds Deutsche Welle.
The World Health Organization has “said it understood why a country facing the sort of increases in cases, hospitalisations and deaths that were happening in the UK might decide to go beyond the evidence” on administration of second doses, The Guardian reports.
But there is “very little empiric data from the trials that underpin this type of recommendation”, said Dr Joachim Hombach of the UN health agency’s strategic advisory group of experts on immunisation.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
According to the newspaper, “there is some evidence from trials of the Oxford/AstraZeneca vaccine that a late second dose, up to 12 weeks, does not interfere with the efficacy of the vaccine”.
But rival vaccine maker Pfizer has said that no data from its own clinical trials was available “to demonstrate that protection after the first dose is sustained after 21 days”.
Despite the misgivings, some experts believe the gains of delaying vaccine doses may outweigh the risks.
Thomas Mertens, from Germany’s public health agency, the Robert Koch Institute, has come out in favour of the UK plan. “Since the interval between the two vaccinations can very likely vary within wide limits and protection is already very good after one shot, it is certainly worth considering giving preference to the first injection in the event of a vaccine shortage,” he said.
The UK’s Joint Committee on Vaccination and Immunisation, an independent body that advises United Kingdom health departments on immunisation, reports that short-term vaccine efficacy from the first dose of the Pfizer-BioNTech vaccine is calculated at around 90%, and at around 70% for the AstraZeneca vaccine.
Given those high levels of protection, “models suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalisations than vaccinating a smaller number of people with two doses”, the committee’s experts argue.
Create an account with the same email registered to your subscription to unlock access.
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
Why are people and elephants fighting in Sri Lanka?
Under The Radar Farmers encroaching into elephant habitats has led to deaths on both sides
By Chas Newkey-Burden, The Week UK Published
-
Indie film's 'very brief' use of AI sparks backlash and calls for boycotts
Talking Points Did the creators of a new horror movie make a deal with the artificial intelligence devil?
By Rafi Schwartz, The Week US Published
-
Could Taylor Swift swing the election?
Today's Big Question The pop star has outsized influence — and that extends beyond the music industry
By Anya Jaremko-Greenwold Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published
-
China's pneumonia cases: should we be worried?
The Explainer Experts warn against pushing 'pandemic panic button' following outbreak of respiratory illness
By Keumars Afifi-Sabet, The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published